Control Clin Trials

• 

  Publication Venue For

  • Enrollment in clinical trials according to patients race: experience from the VA Cooperative Studies Program (1975-2000)..  25:378-387. 2004
  • Data monitoring and large apparent treatment effects..  25:67-69. 2004
  • Stop Hypertension with the Acupuncture Research Program (SHARP): clinical trial design and screening results..  25:76-103. 2004
  • Lessons learned from the DIG trial..  24:316S-326S. 2003
  • A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods..  24:629-642. 2003
  • Constructing a database of individual clinical trials for longitudinal analysis..  24:324-340. 2003
  • Toward protecting the safety of participants in clinical trials..  24:256-271. 2003
  • Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors..  24:206-223. 2003
  • A note on statistical methods for assessing therapeutic equivalence..  23:515-520. 2002
  • Quality control within the Asthma Clinical Research Network..  22:207S-221S. 2001
  • Graphical search for two-stage designs for phase II clinical trials..  22:367-372. 2001
  • A multicenter two by two factorial trial of cognitive behavioral therapy and aerobic exercise for Gulf War veterans' illnesses: design of a veterans affairs cooperative study (CSP #470)..  22:310-332. 2001
  • Knowledge of fraud among biostatisticians..  22:263-264. 2001
  • Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years..  21:356S-378S. 2000
  • Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud..  21:415-427. 2000
  • A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs..  20:601-619. 1999
  • Data monitoring committees and interim monitoring guidelines..  20:395-407. 1999
  • The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group..  20:91-120. 1999
  • A design alternative for two-stage, phase II, multicenter cancer clinical trials..  19:440-450. 1998
  • Guidelines for quality assurance in multicenter trials: a position paper..  19:477-493. 1998
  • Cooperative studies in health services research in the Department of Veterans Affairs..  19:134-148. 1998
  • Developing systems for cost-effective auditing of clinical trials..  18:651-660. 1997
  • A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931..  18:286-300. 1997
  • Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)..  18:358-377. 1997
  • The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial..  17:304-315. 1996
  • Discussion of "inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 - The perspective of NIH clinical trialists".  16:301-303. 1995
  • A comparison of two methods of estimating a common risk difference in a stratified analysis of a multicenter clinical trial..  15:135-153. 1994
  • Erratum: (Controlled Clinical Trials, Volume 14, Number 6, December 1993, page 511, 512, 515).  15:326. 1994
  • Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]..  14:511-522. 1993
  • Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials..  14:6-18. 1993
  • Suspended judgment. Clinical trials of informed consent..  13:321-324. 1992
  • Methods, statistical features, and baseline results of a standardized, multicentered ophthalmologic surgical trial: the Silicone Study..  12:438-455. 1991
  • Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints.  11:268. 1990
  • Selection bias in a randomized controlled clinical trial.  11:258. 1990
  • ·P-18 Need an endpoint for a clinical trial? Just ask.  11:284. 1990
  • Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry..  10:57-70. 1989
  • Use of ejection fraction as a surrogate endpoint for death in clinical trials of acute myocardial infraction.  10:349. 1989
  • Utilization of the National Death Index-A classification problem. Impact of changes in the NDI matching criteria evaluated with the Coronary Artery Surgery Study (CASS) data.  9:242. 1988
  • Admissible two-stage designs for phase II cancer clinical trials 2003